Welcome to our dedicated page for BIVN news (Ticker: BIVN), a resource for investors and traders seeking the latest updates and insights on BIVN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIVN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIVN's position in the market.
VectorY Therapeutics announces Jim Scibetta as new CEO, while former CEO Sander van Deventer transitions to President of R&D. The company's lead program, VTx-002, a vectorized antibody targeting TDP-43 for ALS treatment, advances to IND-enabling studies following positive FDA feedback. The company recently completed a $138 million Series A funding round co-led by EQT Life Sciences and Forbion, and expanded its presence with a new office in Boston.
Scibetta brings over 20 years of executive leadership experience, including roles as CEO of Maverick Therapeutics and President of Pacira BioSciences. VTx-002 aims to delay ALS disease progression by targeting TDP-43 pathology and is expected to enter clinical trials by the end of 2025.
